| Diabetes Mellitus
Fiasp vs Novolog 70/30
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus.Deep comparison between: Fiasp vs Novolog Mix 70/30 with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNovolog Mix 70/30 has a higher rate of injection site reactions vs Fiasp based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Novolog Mix 70/30 but not Fiasp, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Fiasp
Novolog Mix 70/30
At A Glance
SC injection
With meals
Rapid-acting insulin analog
SC injection
Twice daily
Insulin analog
Indications
- Diabetes Mellitus
- Diabetes Mellitus
Dosing
Diabetes Mellitus - SC injection Inject at start of meal or within 20 minutes after starting a meal into abdomen, upper arm, or thigh; generally use with intermediate- or long-acting insulin; individualize dose based on metabolic needs and blood glucose monitoring.
Diabetes Mellitus - Insulin pump (CSII) Administer by continuous SC infusion using an insulin pump; change FIASP reservoir at least every 6 days or PumpCart at least every 4 days; do not mix with other insulins in the pump.
Diabetes Mellitus - IV infusion Administer only under medical supervision; dilute to 0.5-1 unit/mL in polypropylene infusion bags with 0.9% sodium chloride or 5% dextrose; stable at room temperature for 24 hours.
Diabetes Mellitus Inject subcutaneously in the abdominal region, buttocks, thigh, or upper arm twice daily within 15 minutes before meal initiation (or after meal initiation for type 2 patients); individualize dose based on metabolic needs, blood glucose monitoring results, and glycemic control goal.
Contraindications
- Episodes of hypoglycemia
- Known hypersensitivity to insulin aspart or any excipient in FIASP
- Episodes of hypoglycemia
- Hypersensitivity to Novolog Mix 70/30 or one of its excipients
Adverse Reactions
Most common (>=5%) Nasopharyngitis, upper respiratory tract infection, nausea, diarrhea, back pain (adults with T1D); urinary tract infection (adults with T2D); viral upper respiratory tract infection, upper respiratory tract infection, influenza, headache, pyrexia, vomiting (pediatric T1D)
Serious Hypoglycemia, hypokalemia, severe hypersensitivity reactions including anaphylaxis, angioedema, bronchospasm, hypotension, and shock; lipodystrophy; injection or infusion site reactions; peripheral edema; weight gain
Postmarketing Localized cutaneous amyloidosis at injection site; hyperglycemia with repeated injections into amyloidosis areas; hypoglycemia with sudden change to unaffected injection site
Most common (>=5%) Hypoglycemia, headache, influenza-like symptoms, dyspepsia, back pain, diarrhea, pharyngitis, rhinitis, skeletal pain, upper respiratory tract infection, neuropathy, abdominal pain
Serious Severe hypoglycemia requiring assistance or parenteral glucose/glucagon, anaphylaxis, lipodystrophy, localized cutaneous amyloidosis
Postmarketing Localized cutaneous amyloidosis at injection site, hyperglycemia with repeated injections into areas of amyloidosis, hypoglycemia with sudden change to unaffected injection site, medication errors due to accidental substitution
Pharmacology
Rapid-acting insulin analog; binds to insulin receptors to lower blood glucose by facilitating cellular uptake of glucose into skeletal muscle and adipose tissue and inhibiting hepatic glucose output, while also inhibiting lipolysis and proteolysis and enhancing protein synthesis.
Biphasic insulin analog consisting of 70% insulin aspart protamine (prolonged absorption) and 30% soluble insulin aspart (rapid absorption); lowers blood glucose by stimulating peripheral glucose uptake in skeletal muscle and fat and by inhibiting hepatic glucose production.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Fiasp
- Covered on 5 commercial plans
- PA (8/12) · Step Therapy (9/12) · Qty limit (8/12)
Novolog Mix 70/30
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (0/12)
UnitedHealthcare
Fiasp
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Novolog Mix 70/30
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Fiasp
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Novolog Mix 70/30
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Fiasp.
No savings programs available for Novolog Mix 70/30.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Novolog Mix 70/30View full Novolog Mix 70/30 profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.